J.P. Morgan on Wednesday upgraded Illumina (ILMN) to Overweight from Neutral and raised its December 2026 price target to $185 from $125, citing a favorable outlook for the gene sequencing company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results